New England Journal of Medicine· 2019Q1· Clinical trial

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi, Lars Køber et al.

6,927citations
Q1SCImago
2019year

Short summary

Dapagliflozin significantly reduced the risk of worsening heart failure or cardiovascular death by 26% in patients with heart failure and reduced ejection fraction, regardless of diabetes status.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine